Rosetta Blooms, FLXN Knocked Down, RNA In Demand, Concert Strikes Sweet Note

BioBlast Pharma Ltd. (ORPN: Quote), on Wednesday, announced positive preclinical and clinical pharmacokinetic data on Cabaletta, its drug candidate for patients suffering from oculopharyngeal muscular dystrophy.

The company also announced that according to initial interim safety and tolerability analysis, there were no drug related adverse events in patients in an ongoing phase 2/3 study evaluating Cabaletta in treatment of Oculopharyngeal Muscular Dystrophy, dubbed HOPEMD.

ORPN closed Wednesday's trading at $8.60, up 1.18%.

Concert Pharmaceuticals Inc. (CNCE: Quote) has initiated a phase 1 clinical trial of CTP-730 in healthy subjects. CTP-730 is a novel product candidate that is being developed for the treatment of inflammatory diseases under the company's strategic collaboration with Celgene Corp. (CELG: Quote).

The phase I study is designed to enroll up to 40 healthy subjects and is expected to be completed in 2015.

CNCE closed Wednesday's trading at $13.79, up 5.27%.

Eagle Pharmaceuticals Inc. (EGRX: Quote) announced that Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. (TEVA: Quote), has moved to dismiss with prejudice its first lawsuit, filed last October, alleging that Eagle's tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents.

However, a second lawsuit which alleges that Eagle's bendamustine product infringes Cephalon's newly-issued U.S. Patent remains pending.

Eagle's New Drug Application for its bendamustine product received tentative approval for the treatment of Indolent B-cell non-Hodgkin lymphoma from the FDA on July 22, 2014. Due to orphan drug exclusivity held by Cephalon, the tentative approval will not convert to final approval until September 2015.

EGRX closed Wednesday's trading at $12.67, up 4.54%.

Continue reading here:
Rosetta Blooms, FLXN Knocked Down, RNA In Demand, Concert Strikes Sweet Note